Effects of varenicline in adult smokers: A multinational, 24-week, randomized, double-blind, placebo-controlled study

Clinical Therapeutics

Volumn 33, Issue 4, 2011, Pages 465-477

  Bolliger, Chris T ^a   Issa, Jaqueline S ^b   Posadas Valay, Rodolfo ^c   Safwat, Tarek ^d   Abreu, Paula ^e   Correia, Eurico A ^e   Park, Peter W ^e   Chopra, Pravin ^e  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e PFIZER INC   (United States)

Author keywords

Continuous abstinence rate; Randomized trial; Smoking cessation; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ADULT; AGED; AGGRESSION; AGITATION; ANGER; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; AUTOMUTILATION; BEHAVIOR DISORDER; BLUNTED AFFECT; BRAZIL; CIGARETTE SMOKING; COLOMBIA; CONSTIPATION; CONTROLLED STUDY; COSTA RICA; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTHYMIA; EGYPT; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFECTION; INFERTILITY; INFESTATION; INFLUENZA; INSOMNIA; JORDAN; LEBANON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MEXICO; MOOD CHANGE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NIGHTMARE; OBSESSION; OUTCOME ASSESSMENT; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SOUTH AFRICA; STRESS; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT DURATION; UNITED ARAB EMIRATES; VENEZUELA;

EID: 79957648024     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.013     Document Type: Article

References (26)

1. The World Report 2002: reducing risks, promoting healthy life World Health Organization, Accessed March 30, 2010. http://www.who.int/whr/2002/en/whr02_en.pdf.
2. Wipfli H., Samet J.M. Global economic and health benefits of tobacco control: part 1. Clin Pharmacol Ther 2009, 86:263-271.
3. Stead L.F., Perera R., Bullen C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, CD000146.
4. Fiore M.C., Jaén C.R., Baker T.B., et al. Clinical practice guideline. Treating tobacco use and dependence: 2008 update US Dept of Health and Human Services, Public Health Service, Accessed March 30, 2010. http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.
5. Stapleton J.A., Watson L., Spirling L.I., et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008, 103:146-154.
6. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55. Varenicline Phase 3 Study Group.
7. WHO report on the global tobacco epidemic, 2009: implementing smoke-free environments World Health Organization, Accessed March 30, 2010. http://whqlibdoc.who.int/publications/2009/9789241563918_eng_full.pdf.
8. Global Adult Tobacco Survey (GATS): Fact Sheet: Brazil Centers for Disease Control and Prevention, Accessed March 30, 2010. http://www.cdc.gov/tobacco/global/gats/countries/amr/fact_sheets/brazil/.
9. Encuesta Nacional de Adicciones [National Survey on Addictions], 2008 Instituto Nacional de Salud Publica [National Institute of Public Health], Accessed March 30, 2010. http://www.conadic.salud.gob.mx/pie/ena2008.html.
10. Mackay J., Eriksen M., Shafey O. The Tobacco Atlas 2006, American Cancer Society, Atlanta, Ga. 2nd ed.
11. WMA Declaration of Helsinki-Ethical principles for medical research involving human subjects World Medical Association, Accessed March 30, 2010. http://www.wma.net/en/30publications/10policies/b3/index.html.
12. The ICH Process for Harmonization of Guidelines The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Accessed March 30, 2010. http://www.ich.org/about/process-of-harmonisation.html.
13. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991, 86:1119-1127.
14. You can quit smoking. Consumer guide US Dept of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality, Accessed March 30, 2010. http://www.ahrq.gov/consumer/tobacco/quits.htm.
15. Counseling to prevent tobacco use and tobacco-caused disease: recommendation statement Preventive Services Task Force, Accessed March 30, 2010. http://www.uspreventiveservicestaskforce.org/uspstf/uspstbac.htm.
16. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial [published correction appears in: JAMA. 2006;296:1355]. JAMA 2006, 296:56-63. Varenicline Phase 3 Study Group.
17. Gonzales D.H., Nides M.A., Ferry L.H., et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001, 69:438-444.
18. Jorenby D.E., Leischow S.J., Nides M.A., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340:685-691.
19. Tsai S.T., Cho H.J., Cheng H.S., et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007, 29:1027-1039.
20. Wang C., Xiao D., Chan K.P., et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009, 14:384-392.
21. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011, CD006103.
22. Moore T.J., Glenmullen J., Furberg C.D. Prescription drugs associated with reports of violence towards others. PLoS One 2010, 5:e15337.
23. Moore T.J., Glenmullen J., Furberg C.D. Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother 2010, 44:1389-1394.
24. Purvis T.L., Nelson L.A., Mambourg S.E. Varenicline use in patients with mental illness: an update of the evidence. Expert Opin Drug Saf 2010, 9:471-482.
25. Tonstad S., Davies S., Flammer M., et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010, 33:289-301.
26. Faessel H., Ravva P., Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009, 31:177-189.